Smith & Nephew stock slips to 52-week low as new USD bond reshapes debt profile
Published on 09/11/2026 at 17:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Smith & Nephew stock (ISIN GB0009223206) has fallen to a 52-week low of USD 27.54 on September 11, 2026, even as the medical technology group priced USD 700 million of new 5.750 percent notes due 2036 to refinance part of its 2030 bond stack.
New USD bond extends debt maturity to 2036
According to StockTitan on September 10, 2026, Smith & Nephew plc is issuing USD 700,000,000 aggregate principal amount of 5.750 percent notes due 2036 under its existing Form F-3 debt shelf.
The prospectus supplement filed with the United States Securities and Exchange Commission shows that the new notes carry a fixed coupon of 5.750 percent per year, with interest payments scheduled semi-annually on March 11 and September 11, starting March 11, 2027, and a maturity date of September 11, 2036.StockTitan
As ADVFN reported on September 10, 2026, management intends to use the net proceeds primarily to fund a cash tender offer for its outstanding 2.032 percent senior notes due 2030, effectively extending the firm’s debt maturity profile from 2030 out to 2036.
In a related disclosure, Smith & Nephew announced a tender offer of up to USD 250 million for the 2030 bonds, illustrating that only part of the existing notes will be repaid and leaving the company with a mix of shorter and longer-dated debt.StockTitan
Stock under pressure at 52-week low
While the bond issue strengthens long-term funding, investor sentiment toward Smith & Nephew stock remains cautious, with its American Depositary Shares listed on the New York Stock Exchange under the ticker SNN trading at a 52-week low of USD 27.54 on September 11, 2026.Investing.com
The same Investing.com overview notes that over the past twelve months the shares have fallen 26.81 percent, underscoring the extent of the setback relative to the prior year level and highlighting that the debt initiative comes against a backdrop of sustained share price weakness.Investing.com
Separately, Smith & Nephew’s ordinary shares on the London Stock Exchange under the ticker SN closed at 1,031.00 pence on September 10, 2026, representing a daily gain of 0.5 percent and leaving the stock 17.20 percent lower year-to-date, according to a recent price snapshot.Ad-hoc-news
Analyst signals and market-cap context
The SEC filing summarised by StockTitan shows Smith & Nephew’s market capitalization at around USD 11.56 billion as of early September 2026, placing the group alongside mid to large-cap global medtech peers in terms of equity value.
In the bond-pricing coverage, TipRanks data cited by The Globe and Mail indicates that the most recent analyst view on SNN is a Hold rating with a USD 30.00 price target, implying modest upside of around 9 percent from the 52-week low trading level of USD 27.54.The Globe and Mail
The same TipRanks-based overview notes that an AI-derived Spark Analyst designation classifies SNN as Outperform, suggesting that quantitative screening tools see the bond-financed balance sheet repositioning as broadly supportive even though the share price remains close to its recent low.The Globe and Mail
Debt refinancing and investor perspective
For investors, the key quantified takeaway is that Smith & Nephew is replacing part of its 2.032 percent 2030 notes with higher-coupon 5.750 percent 2036 debt, trading near a 52-week share price low and a one-year performance of minus 26.81 percent, while carrying an equity market capitalization of roughly USD 11.56 billion as of early September 2026.StockTitan
This combination of a longer debt maturity profile, increased interest expense and share price weakness frames the current Smith & Nephew stock story on September 11, 2026, with upcoming quarters likely to show whether the refinancing and ongoing operational initiatives can translate into improved earnings and a recovery from the present 52-week low zone.
Smith & Nephew stock key data
- Company: Smith & Nephew plc
- ISIN: GB0009223206
- Ticker: SN (London), SNN (NYSE ADR)
- Trading venue: London Stock Exchange (primary, SN); New York Stock Exchange ADR (SNN)
- Price (as of September 11, 2026): 27.54 USD (NYSE ADR, 52-week low)
- Market capitalization: 11.56 billion USD (as of September 8, 2026)
- Sector / Industry: Health Care / Medical Technology
- Index membership: FTSE 100
